This is an ambitious original work of health journalism designed to explore the dangers of Avandia beyond what current research and government action allow. It also suggests that the data it gathered, by its very nature, illustrates weaknesses in the government post-market surveillance system.
It’s an excellent example of enterprise work. Getting documents under the Freedom of Information Act requires considerable time and effort. Both AP and the reporter should be recognized for their commitment to this story.
Having said all that, the article fails to convey key information about the true size of the benefits and risks of the drug to people with type 2 diabetes. It does not mention other treatment options. As a result, the story may unnecessarily frighten Avandia users.
The article fails to report how much the drug costs, especially as compared to generic or other alternatives. If it is a relatively expensive drug, this would provide useful context.
The article should have made clear the absolute risks of the most severe cardiac outcomes in the Type 2 population in general and in Avandia takers specifically. This is especially important given the data the article focuses on clearly misrepresent prevalence. The author cites a 43 percent increase in heart attacks attributed to Avandia in the original New England Journal of Medicine article, but Nissen’s original NEJM report shows that the numbers of heart attacks and deaths were quite small.
The article makes clear the range of side effect severity, properly focusing on the most serious: heart-related hospitalizations and deaths. More information on the benefits of this class of drugs would provide better balance.
The article makes clear that the data it is examining are limited by the anecdotal, voluntary nature of the reports to the federal government. But it fails to specify the harms and benefits of the treatment as reflected in previous research.
The risks of Type 2 diabetes itself and of taking Avandia are real. Still, the citation of a 43 percent increase in risk to Avandia takers, without context and proportion, creates a potentially misleading impression of the drug’s harm.
The article makes clear the affiliations and potential conflicts of interest of key experts interviewed. A small oversight is the failure to mention that the original NEJM piece discloses that author Steve Nissen of the Cleveland Clinic has received research support from a number of diabetes drug makers, none of which is GlaxoSmithKline, Avandia’s maker. That study mentions that consulting fees he gets from various drugmakers (it is not revealed whether that group includes GSK) are donated directly to charity.
The article fails to mention that there are cheaper, effective alternatives to Avandia on the market.
The article makes clear that Avandia is widely used, and that 1 million Americans take it. Given the intent of the article, however, it would have been useful to include an estimate of the drug’s market share, or at least compare the one million to the national type 2 diabetes population.
The author makes clear that the treatment is in widespread use.
The reporter has undertaken considerable original research to do this article.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like